Skip to main content
Premium Trial:

Request an Annual Quote

OGT, Sanger to Co-develop Prenatal Microarray for Genetic Disorders

NEW YORK (GenomeWeb News) - Oxford Gene Technology and the Wellcome Trust Sanger Institute will work together to develop a microarray to test for prenatal genetic defects, OGT said today.
The organizations will co-develop a commercial diagnostic that is expected to be faster and more cost-effective than current prenatal testing methods.
Under the agreement, OGT will use its ink jet in-situ synthesis platform to make a 60-mer oligonucleotide microarray, while Sanger will contribute clinical knowledge in targeting “the most appropriate syndromes,” OGT said.
OGT’s R&D director, John Anson, said the company is developing numerous products for array comparative genomic hybridization applications that will, with Sanger’s contribution, be used to develop and validate an array “with greater resolution and reproducibility.”

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.